Suchergebnisse - (Subject:"ritonavir")

PubPharm (6.437)

71

Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19

enthalten in: Journal of medical virology | 2024

von Chang, L. | Chen, I. | Hung, K.

72

Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness : A Real-World Study

enthalten in: Journal of intensive care medicine | 2024

von Chen, X. | Zhu, Y. | Shen, L. | +3

73

Public Health Impact of Paxlovid as Treatment for COVID-19, United States

enthalten in: Emerging infectious diseases | 2024

von Bai, Y. | Du, Z. | Wang, L. | +7

UpdateOf: medRxiv. 2023 Sep 07;:. - PMID 37732213

74

Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir : Case series and discussion

enthalten in: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists | 2024

von Marsh, J. | Logan, A. | Bilgili, E. | +2

75

Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China : a multicentre, retrospective cohort study

enthalten in: Annals of medicine | 2024

von Han, X. | Li, C. | Yuan, X. | +22

76

Effect of rifampicin administration on CYP induction in a dermatomyositis patient with vasospastic angina attributable to nilmatrelvir/ritonavir-induced blood tacrolimus elevation : A case report

enthalten in: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy | 2024

von Akamatsu, H. | Kohno, Y. | Hashizume, J. | +5

77

Oral COVID-19 Antiviral Uptake Among a Highly Vaccinated US Cohort of Adults With SARS-CoV-2 Infection Between December 2021 and October 2022

enthalten in: Open forum infectious diseases | 2024

von Shen, Y. | Robertson, M. | Kulkarni, S. | +10

78

Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2024

von Carlson, J. | Foos, V. | Kasle, A. | +7

79

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1 : week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

enthalten in: The lancet. HIV | 2024

von Orkin, C. | Molina, J. | Cahn, P. | +112

80

Detailed tracking of antigen and antibody levels during coronavirus disease 2019 treatment in an immunosuppressed patient with anti-neutrophil cytoplasmic autoantibody-associated vasculitis

enthalten in: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy | 2024

von Yukishima, T. | Furuhashi, K. | Shimoyama, K. | +10